IP Library Granted Patent US 10,391,106
Granted Patent B2
US 10,391,106 · App. 15/639,702 · Granted Aug 27, 2019

19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,106
App. No.
15/639,702
Granted
Aug 27, 2019
Kind
B2
Abstract

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R 1 , R 2 , R 3a , R 3b , R 4a , and R 4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Claims (4)

1. A compound of the formula:

2. A pharmaceutically acceptable salt of a compound having the formula:

3. A pharmaceutical composition comprising a compound having the formula:

and a pharmaceutically acceptable excipient.

Assignments (2)
CHANGE OF NAME Recorded Apr 23, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075472/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2022
From: BOTELLA, GABRIEL MARTINEZ; HARRISON, BOYD L.; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.; BERESIS, RICHARD THOMAS
To: SAGE THERAPEUTICS, INC.
Reel/Frame 058974/0917 →
Cited By (5)
US 12,201,640 US 12,358,942 US 12,473,327 US 12,534,495 US 12,655,175